Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Dynasore

Dynasore is a cell-permeable dynamin inhibitor with an IC50 of 15 μM. Dynasore blocks cell migration.

Product Specifications

CAS Number

[304448-55-3]

UNSPSC

12352005

Hazard Statement

H302+H312, H315, H318, H411

Target

Autophagy; Dynamin; HSV; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Cytoskeleton

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Dynasore.html

Purity

99.66

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=C(O)C=C2C=CC=CC2=C1)N/N=C/C3=CC=C(O)C(O)=C3

Molecular Formula

C18H14N2O4

Molecular Weight

322.31

Precautions

H302+H312, H315, H318, H411

References & Citations

[1]Macia E, et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006 Jun;10 (6) :839-50.|[2]Mues MB, et al. Dynasore disrupts trafficking of herpes simplex virus proteins. J Virol. 2015 Jul;89 (13) :6673-84.|[3]Gao D, et al. Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One. 2013 Apr 15;8 (4) :e60967.|[4]Li G, et al. Dynasore Improves Motor Function Recovery via Inhibition of Neuronal Apoptosis and Astrocytic Proliferation after Spinal Cord Injury in Rats. Mol Neurobiol. 2016 Nov 7.|[5]Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25 (1) :24-38.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

HSV-1; HSV-2

Citation 01

AAPS PharmSciTech. 2023 Feb 15;24 (2) :69.|Adv Funct Mater. 2023 Jan 15.|Adv Funct Mater. 2024 May 1.|Adv Healthc Mater. 2024 Jul 16:e2401460.|Adv Mater. 2022 Jul 28; e2204287.|Adv Mater. 2025 Jan 10:e2415030.|Adv Sci (Weinh) . 2023 Feb;10 (4) :e2204871.|Adv Sci (Weinh) . 2025 Sep 3:e02788.|Alzheimers Dement. 2025 Aug;21 (8) :e70331.|Anal Chem. 2020 Jan 21;92 (2) :2103-2111.|Antioxidants (Basel) . 2022 Nov 22;11 (12) :2307.|Arab J Chem. 2020, 13 (1) : 2558-2567.|Autophagy. 2025 May 31:1-21.|Biol Res. 2023 Mar 11;56 (1) :10.|Biomaterials. 2022 May;284:121529.|bioRxiv. 2025 Jul 29.|bioRxiv. 2025 Oct 24.|Cancer Immunol Res. 2022 Jul 1;10 (7) :844-855.|Cell Commun Signal. 2020 Nov 4;18 (1) :176.|Cell Death Differ. 2024 Nov;31 (11) :1519-1533.|Cell Host Microbe. 2025 Sep 30:S1931-3128 (25) 00375-0.|Cell Rep. 2022 Jun 14;39 (11) :110943.|Comput Struct Biotechnol J. 2021;19:1933-1943.|Drug Deliv. 2018 Nov;25 (1) :1066-1079. |EBioMedicine. 2022 Aug:82:104181.|Elife. 2022 Jun 28;11:e78044.|EMBO Rep. 2025 Sep 15.|Environ Health. 2025 Nov 6.|Environ Sci Technol. 2023 Jun 13;57 (23) :8514-8523.|Eur J Cell Biol. 2019 Jan;98 (1) :36-50.|Eur J Pharmacol. 2021 Sep 15:907:174203.|FEBS J. 2025 Mar;292 (5) :1052-1069.|Food Chem. 2024 Sep 8;463 (Pt 1) :141196.|Front Cell Dev Biol. 2021 Jul 7;9:687322.|Genes Dis. 2025 Aug 14.|Immunity. 2025 Jun 10;58 (6) :1469-1483.e8.|Int Immunopharmacol. 2025 Sep 23:162:115167.|Int J Biol Macromol. 2022 Aug 31:215:23-35.|Int J Biol Sci. 2024 Sep 3;20 (12) :4713-4730.|Int J Mol Sci. 2025 Mar 29;26 (7) :3172.|Int J Pharm. 2024 Apr 25:655:124072.|J Am Chem Soc. 2018 Dec 12;140 (49) :17234-17240.|J Cancer. 2025 Jan 27;16 (5) :1466-1478. |J Extracell Vesicles. 2021 Jul;10 (9) :e12117.|J Extracell Vesicles. 2025 Aug;14 (8) :e70146.|J Hazard Mater. 2021 Sep 5;417:126092.|J Virol. 2021 Nov 23;95 (24) :e0134521.|J Virol. 2025 Aug 25:e0022125.|Mov Disord. 2024 Jan;39 (1) :40-52.|Nano Lett. 2019 Nov 13;19 (11) :8010-8020. |Nat Commun. 2021 Jun 9;12 (1) :3481.|Nat Commun. 2025 Aug 27;16 (1) :7994.|Nat Commun. 2025 Nov 13;16 (1) :9973.|Nat Nanotechnol. 2020 Dec;15 (12) :1043-1052.|Nat Plants. 2025 Sep 12.|Neurotox Res. 2019 Jul;36 (1) :108-116.|Oncogene. 2018 Jan 4;37 (1) :116-127. |Plant Biotechnol J. 2025 Aug;23 (8) :3237-3253.|PLoS Pathog. 2021 Jul 21;17 (7) :e1009752.|Redox Biol. 2022 Apr;50:102257.|Redox Biol. 2025 May:82:103581.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2023 Apr 19.|Research Square Preprint. 2023 Aug 7.|Research Square Print. 2022 May.|Sci Bull. 2020 Nov 15;65 (21) :1796-1799.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.|Sci Rep. 2023 May 25;13 (1) :8479.|Signal Transduct Target Ther. 2024 Sep 26;9 (1) :254.|Small Methods. 2021 Apr;5 (4) :e2001047.|SSRN. 14 Feb 2022.|SSRN. 2023 Sep 15.|SSRN. 2025 Sep 30.|Toxins. 2023 Feb 6;15 (2) :132.|Virology. 2024 Dec:600:110233.|Virus Res. 2020 Jan 15;276:197806.|J Autoimmun. 2023 Apr:136:103012.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

RAD17 Antibody
A40176-50UG 50 µg

RAD17 Antibody

Ask
View Details
RABGGTA (NM_004581) Human Tagged Lenti ORF Clone
RC221822L4 10 µg

RABGGTA (NM_004581) Human Tagged Lenti ORF Clone

Ask
View Details
Keratin 10 (KRT10, K10, CK10, KPP, Cytokeratin 10, Epidermolytic Hyperkeratosis, Keratosis Palmaris Et Plantaris)
141122 200 µL

Keratin 10 (KRT10, K10, CK10, KPP, Cytokeratin 10, Epidermolytic Hyperkeratosis, Keratosis Palmaris Et Plantaris)

Ask
View Details
(-) -Norgestrel-d6
165653 1 mg

(-) -Norgestrel-d6

Ask
View Details
RBM12 CRISPR All-in-one AAV vector set (with saCas9)(Rat)
38596156 3x 1.0 µg DNA

RBM12 CRISPR All-in-one AAV vector set (with saCas9)(Rat)

Ask
View Details
PRY2 CRISPRa sgRNA lentivector (set of three targets)(Human)
37884121 3x 1.0µg DNA

PRY2 CRISPRa sgRNA lentivector (set of three targets)(Human)

Ask
View Details